This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETFs in Focus on Alibaba's Mixed Q4 Results
by Sweta Killa
Alibaba shares plunge as it beats earnings estimates but lags the same for revenues. This puts Alibaba-heavy ETFs in focus.
Should You Buy Tesla ETFs Post Q1 Earnings Miss?
by Sweta Killa
Tesla misses first-quarter earnings and revenue estimates but reaffirms its Robotaxi, EV launch plan. Should you buy its ETFs?
Tesla Sees Target Price Cuts Ahead of Q1 Earnings: ETFs in Focus
by Sweta Killa
Tesla's Q1 earnings picture looks bleak, with many analysts lowering their target price.
Tesla Sees Worst Vehicle Sales in 3 Years: ETFs in Focus
by Sweta Killa
Tesla reports its worst quarter for sales in three years. This puts Tesla-heavy ETFs in focus.
Here's Where Tesla Stands Amid Auto Tariffs: ETFs in Focus
by Yashwardhan Jain
Take a look at how can Tesla be affected by auto tariffs, which have rattled the automaker market.
Tesla Stock Suffers Worst Day Since 2020: ETFs in Focus
by Sanghamitra Saha
Tesla shares just saw the worst trading day since 2020. Are moderate short-term gains likely?
The Zacks Analyst Blog Alibaba, PGJ, FNS, CGRO and Nightview
by Zacks Equity Research
Alibaba, PGJ, FNS, CGRO and Nightview are included in this Analyst Blog.
Alibaba's Stock Surges on AI Breakthrough: ETFs in Focus
by Sanghamitra Saha
Alibaba (BABA) experienced its biggest stock surge in weeks after introducing the QwQ-32B model, an AI system that rivals DeepSeek but requires only a fraction of the data.
Alibaba Jumps Post Q3 Earnings: ETFs to Buy
by Sweta Killa
Alibaba records its fastest pace of revenue growth in more than a year, spreading cheer among investors.
Airbnb Stock Surges Post Earnings: ETFs to Win
by Sanghamitra Saha
Airbnb (ABNB) shares jumped 14.5% on Feb. 14, 2024, after the company reported fourth-quarter earnings and revenue that beat analysts' estimates.
Tesla Misses on Q4 Earnings, Vows to Return to Growth: ETFs to Buy
by Sweta Killa
Tesla misses fourth-quarter earnings and revenue estimates but pledges a return to growth in 2025. Investors should tap the opportune moment with these ETFs.
Will Q4 Earnings Make or Break Tesla ETFs?
by Sweta Killa
Tesla has a reasonable chance to beat earnings estimates in the to-be-reported quarter.
Tesla Slips on Q4 Delivery Miss: ETFs in Focus
by Sweta Killa
Tesla misses estimates for Q4 deliveries and sees the first year-over-year decline in deliveries for 2024.
Top Events of 2024 & ETF Predictions for 2025
by Sanghamitra Saha
Expect strength in Wall Street in 2025, with potential in blend stocks, an AI boom, a Chinese equities rebound and a strong year for Tesla.
Tesla Stock Hits All-Time High: ETFs to Ride the Momentum
by Sanghamitra Saha
Tesla shares hit an all-time high. Several analysts raised price targets. How can you play TSLA stock with lower level of risks? Tap Tesla-focused ETFs.
Can Tesla Return to Its Golden Days? ETFs in Focus
by Sanghamitra Saha
Tesla (TSLA) stock has slumped 11.3% so far this year. Will we see more pain ahead?
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
by Indrajit Bandyopadhyay
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
by Zacks Equity Research
Key highlights of the past week are merger agreements plus regulatory and pipeline developments.
Biogen to Acquire Gene-Therapy Company Nightstar for $800M
by Zacks Equity Research
Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.
Company News For Mar 5, 2019
by Zacks Equity Research
Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Nightstar Therapeutics (NITE) was a big mover last session, as the company saw its shares rise more than 6% on the day.